Octillion

Octillion Biosciences is a preclinical-stage biotechnology company dedicated to developing transformative therapies that target the biological drivers of aging. The company utilizes a proprietary platform to identify and modulate cellular senescence, a state of permanent cell cycle arrest that contributes to chronic inflammation and tissue dysfunction. By developing small molecule senolytics and senomorphics, Octillion aims to treat a broad range of age-related conditions, including metabolic and fibrotic diseases. Headquartered in San Francisco, the company is led by experts in bioengineering and data science and is backed by prominent venture capital firms like Atlas Venture. Their approach combines high-throughput screening with deep biological insights to rejuvenate tissues and extend healthy lifespan.